Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) today announced that its wholly owned subsidiary, HealthTab(TM), has entered into a non-exclusive, pilot supplier distribution agreement in Canada with Abbott, the global health care company, with respect to the handheld blood chemistry analyzer, i-STAT Alinity. Under the agreement, HealthTab will distribute Abbott’s point-of-care i-STAT Alinity and its associated tests for creatinine in Canadian pharmacies to better support patients with important information about their renal function. “Understanding renal function in patients at risk from or already living with chronic disease is critical,” said Hector Bremner, CEO of Avricore Health. “With i-STAT Alinity and its associated test for creatinine, health care professionals can obtain results in approximately two minutes to detect elevated levels of creatinine that are associated with abnormal renal function.”
To view the full press release, visit https://ibn.fm/M2y2E
About Avricore Health Inc.
Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab(TM) (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. For more information about the company, visit www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork